acute bacterial skin
Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
... for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP), such as Staphylococcus aureus and Streptococcus ...
10
Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin
... Abstract: The increase in hospitalization due to acute bacterial skin and skin structure infections (ABSSSI) caused by resistant pathogens supports the need for new treatment options. ...
10
Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
... Abstract: Acute bacterial skin and skin structure infections (ABSSSI) are a common disease causing patients to seek treatment through the health care ...drug-resistant bacterial ...
10
Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections
... of acute bacterial skin and skin structure infections ...on bacterial killing is optimized by the free-drug area under the curve to minimum inhibi- tory concentration ratio ...
8
<p>Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials</p>
... Purpose: To assess the clinical ef fi cacy and safety of dela fl oxacin for treating acute bacterial skin and skin structure infections (ABSSSIs) in adult patients.. Patients and methods: [r] ...
9
Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review
... and skin and skin structure infection studies (Figure ...complicated skin and soft tissue ...of acute bacterial skin and skin structure infections (ABSSSIs) caused by ...
9
Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections
... of acute bacterial skin and skin-structure infections in its first Phase III clinical ...in acute bacterial skin and skin-structure infections, providing a safe ...
23
<p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>
... Acute bacterial skin and skin-structure infections (ABSSSIs) are de fi ned as bacter- ial infections of the skin with a lesion area of at least 75 cm 2 ...
10
Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections
... in acute bacterial skin and skin structure infections, such as strains of Staphylo- coccus aureus (including methicillin-resistant ...with skin and skin structure infections ...
18
New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
... with acute bacterial skin and skin structure ...excellent skin and soft tissue penetration, bactericidal activity against Gram-positive bacteria including methicillin- resistant ...
8
Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection
... of acute bacterial skin and skin structure infection (ABSSSI) caused by Gram-positive bacteria in the United States, Europe, and other ...
15
Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections
... of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria in adults in August ...inhibits bacterial cell wall synthesis and is rapidly ...
9
Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.
... Administration (FDA) and the European Medicines Agency (EMA) for use as a single-dose treatment of acute bacterial skin and skin structure infections (ABSSSI). Approvals were based on results ...
9
Treatment outcome measures for randomized controlled trials of antibiotic treatment for acute bacterial skin and skin structure infections in the emergency department setting
... Acute bacterial skin and skin structure infections (ABSSSIs), which include cellulitis, abscesses, and wound infections, are among the most commonly encountered conditions in emergency ...
7
Systematic review and network meta analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA
... ABSSSI: Acute bacterial skin and skin structure infection; AE: Adverse event; CI: Confidence interval; CrI: Credible interval; cSSSI: Complicated skin and skin structure ...
11
Ceftaroline Fosamil Therapy in Patients With Acute Bacterial Skin and Skin Structure Infections With Systemic Inflammatory Signs: A Retrospective Dose Comparison Across Three Pivotal Trials.
... Acute bacterial skin and skin-structure infections (ABSSSIs) and complicated skin and soft-tissue infections (cSSTIs) include cellulitis/erysipelas, wound infection and major cutaneous ...
8
Examination of hospital length of stay in Canada among patients with acute bacterial skin and skin structure infection caused by methicillin-resistant <em>Staphylococcus aureus</em>
... with acute services in the hospital]), administration of antibiotics, and surgical procedures (incision, drainage, surgical debridement, wound excision, and ...
15
Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department
... a skin infection (ICD-9680–686) in our study’s EDs during the enrollment time period (data not ...their skin infection based on lesion size, yet not exclude those with history of failure or multiple in- ...
11
The Penicillin for the Emergency Department Outpatient treatment of CELLulitis (PEDOCELL) trial: update to the study protocol and detailed statistical analysis plan (SAP)
... for acute bacterial skin and skin structure infections (ABSSSI), which directly im- pacted on the proposed primary and secondary outcome measures to be utilized in the previous version of this ...
9
New developments in the management of severe skin and deep skin structure infections – focus <br /> on tedizolid
... Abstract: Tedizolid, a novel oxazolidinone, is approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs). Tedizolid offers several potential advantages over ...
6